EA201290072A1 - Полимерные частицы и их применение - Google Patents

Полимерные частицы и их применение

Info

Publication number
EA201290072A1
EA201290072A1 EA201290072A EA201290072A EA201290072A1 EA 201290072 A1 EA201290072 A1 EA 201290072A1 EA 201290072 A EA201290072 A EA 201290072A EA 201290072 A EA201290072 A EA 201290072A EA 201290072 A1 EA201290072 A1 EA 201290072A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
polymer particles
relates
polymeric particles
conditions
Prior art date
Application number
EA201290072A
Other languages
English (en)
Inventor
Бернд Хельмут Адам Рем
Натали Энн Парлэйн
Дэвид Нэйл Ведлок
Брайс Малькольм Бадл
Original Assignee
Бернд Хельмут Адам Рем
Натали Энн Парлэйн
Дэвид Нэйл Ведлок
Брайс Малькольм Бадл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бернд Хельмут Адам Рем, Натали Энн Парлэйн, Дэвид Нэйл Ведлок, Брайс Малькольм Бадл filed Critical Бернд Хельмут Адам Рем
Publication of EA201290072A1 publication Critical patent/EA201290072A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к полимерным частицам и их применению. В частности, изобретение относится к функционализированным полимерным частицам, способам получения и их применению для обеспечения клеточного иммунного ответа и лечения или профилактики заболеваний или состояний, включая заболевания или состояния, вызванные внутриклеточными патогенами.
EA201290072A 2009-07-29 2010-07-29 Полимерные частицы и их применение EA201290072A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22931809P 2009-07-29 2009-07-29
US22934809P 2009-07-29 2009-07-29
PCT/IB2010/053465 WO2011013097A2 (en) 2009-07-29 2010-07-29 Polymer particles and uses thereof

Publications (1)

Publication Number Publication Date
EA201290072A1 true EA201290072A1 (ru) 2012-12-28

Family

ID=43529777

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290072A EA201290072A1 (ru) 2009-07-29 2010-07-29 Полимерные частицы и их применение

Country Status (11)

Country Link
US (3) US20120201846A1 (ru)
EP (1) EP2461822A4 (ru)
JP (1) JP2013500329A (ru)
KR (1) KR20140015127A (ru)
CN (2) CN102573891B (ru)
AU (1) AU2010277222A1 (ru)
CA (1) CA2769645A1 (ru)
EA (1) EA201290072A1 (ru)
SG (1) SG178144A1 (ru)
WO (1) WO2011013097A2 (ru)
ZA (1) ZA201201482B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180974B (zh) * 2011-03-22 2013-12-11 兰州大学 一种结核杆菌融合蛋白及其制备方法和应用
US9926346B2 (en) 2012-04-16 2018-03-27 Aeras Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof
WO2013190453A2 (en) * 2012-06-18 2013-12-27 Tracy Thompson Compositions for separation methods
CN102716474B (zh) * 2012-06-27 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用
MX2015000446A (es) * 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
US20140073022A1 (en) * 2012-09-10 2014-03-13 Wisconsin Alumni Research Foundation Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source
LT3102613T (lt) * 2014-02-04 2021-09-27 Polybatics Limited Polimero dalelės ir jų panaudojimas
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
CN108700590B (zh) 2015-03-06 2021-03-02 英国质谱公司 细胞群体分析
GB2555921B (en) 2015-03-06 2021-09-15 Micromass Ltd Endoscopic tissue identification tool
EP3800657A1 (en) * 2015-03-06 2021-04-07 Micromass UK Limited Desorption electrospray ionisation mass spectrometry ("desi-ms") and desorption electroflow focusing ionisation ("deffi-ms") analysis of biological samples on swabs
CA2978042A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
CN107646089B (zh) 2015-03-06 2020-12-08 英国质谱公司 光谱分析
US11282688B2 (en) 2015-03-06 2022-03-22 Micromass Uk Limited Spectrometric analysis of microbes
EP3265823B1 (en) 2015-03-06 2020-05-06 Micromass UK Limited Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US11454611B2 (en) 2016-04-14 2022-09-27 Micromass Uk Limited Spectrometric analysis of plants
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
KR102107519B1 (ko) * 2018-06-25 2020-05-07 경상대학교산학협력단 브루셀라 어보투스 균주 유래의 InpB, Dps, AspC 및 Ndk 단백질을 유효성분으로 포함하는 브루셀라 감염증 예방 또는 치료용 백신 조성물
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
CN109813884A (zh) * 2019-03-25 2019-05-28 中国动物卫生与流行病学中心 一种牛结核病γ-干扰素快速检测制品
CN110411907B (zh) * 2019-06-19 2020-05-22 上海交通大学 植物叶片上亚微米颗粒物凝并效率测定方法、系统及介质
GB201913716D0 (en) * 2019-09-24 2019-11-06 Imp College Innovations Ltd Methods
JP2021187810A (ja) * 2020-06-04 2021-12-13 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP0972045A1 (en) * 1997-04-02 2000-01-19 Statens Seruminstitut NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS)
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
DE10240035A1 (de) * 2002-08-30 2004-03-11 Rehm, Bernd H.A., PD Dr.rer.nat. Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind
JP5557415B2 (ja) * 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
BRPI0612833A2 (pt) * 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
JP2009509530A (ja) * 2005-09-27 2009-03-12 ヘルムート アダム レフム，ベルン ポリマー粒子およびその使用
CN100518821C (zh) * 2006-09-14 2009-07-29 复旦大学 Ag85B,ESAT-6的嵌合疫苗

Also Published As

Publication number Publication date
CN106421743A (zh) 2017-02-22
EP2461822A4 (en) 2013-07-17
WO2011013097A3 (en) 2011-04-07
KR20140015127A (ko) 2014-02-06
CN102573891B (zh) 2016-06-01
CA2769645A1 (en) 2011-02-03
WO2011013097A2 (en) 2011-02-03
AU2010277222A1 (en) 2012-03-08
CN102573891A (zh) 2012-07-11
US20160175419A1 (en) 2016-06-23
JP2013500329A (ja) 2013-01-07
ZA201201482B (en) 2012-11-28
US20180015156A1 (en) 2018-01-18
US20120201846A1 (en) 2012-08-09
SG178144A1 (en) 2012-03-29
EP2461822A2 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
EA201290072A1 (ru) Полимерные частицы и их применение
CY1120557T1 (el) Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων
EA201391392A1 (ru) Синтетические наноносители с осмотически опосредованным высвобождением
MX2021015329A (es) Composiciones a base de nanoparticulas.
BR112013007286A2 (pt) composição polimérica, película e bolsa de autoclave.
EA201400579A1 (ru) Антитела к il-36r
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
ECSP12012105A (es) Antídotos de Anticoagulantes
BR112015008245A2 (pt) composições poliméricas de tratamento.
EA201391041A1 (ru) Растворимые в воде мембранные белки и способы их получения и применения
MY169328A (en) Compositions for the treatment of dry eye
IN2012DN02737A (ru)
EA201001372A1 (ru) Формы рифаксимина и их применение
DK2452658T3 (da) Individuelt tilpasset kompressions-/fastholdelsesortose til at forstærke den muskulære aponeurosepumpe i læggen
BR112013004846A2 (pt) ''menbrana antimicrobiana,filtro,dispositivo de purificação de água e processo para fazer uma menbrana antimicrobiana''.
WO2012129341A3 (en) Disease detection in plants
GB201111609D0 (en) Copolymers and membranes
PH12014502680A1 (en) Polysaccharide compositions and methods of use
BR112015010597A2 (pt) secagem mediante mistura de polissacarídeo nanofibrilado".
TN2013000388A1 (en) Anticoagulant antidotes
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201290243A1 (ru) Хиназолиновые соединения
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies
EP2899216A4 (en) FUNCTIONALIZED OLEFIN POLYMER AND HARDENED COMPOSITION AND HARDENED OBJECT
EP3150632A3 (en) Anti-ricin antibodies and uses thereof